Evidence map›Paper›PMID 32637350›Full record

ArticleFrontiers in oncology2020

Evaluation of the Anti-Tumor Activity of the Humanized Monoclonal Antibody NEO-201 in Preclinical Models of Ovarian Cancer.

Kristen P Zeligs, Maria Pia Morelli, Justin M David, Monica Neuman, Lidia Hernandez, Stephen Hewitt, Michelle Ozaki, Akosua Osei-Tutu, David Anderson, Thorkell Andresson and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. The emerging roles of CEACAM6 in human cancer (Review).International journal of oncology · 2024
    Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 1 country.

Kristen P ZeligsWomen's Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.
Maria Pia MorelliWomen's Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.
Justin M DavidPrecision Biologics, Inc., Bethesda, MD, United States.
Monica NeumanWomen's Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.
Lidia HernandezWomen's Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.
Stephen HewittWomen's Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.
Michelle OzakiWomen's Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.
Akosua Osei-TutuWomen's Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.
David AndersonWomen's Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.
Thorkell AndressonProtein Characterization Laboratory of the Cancer Research Program (CRTP)/Mass Spectrometry Center, National Institutes of Health, Fredrick, MD, United States.
Sudipto DasProtein Characterization Laboratory of the Cancer Research Program (CRTP)/Mass Spectrometry Center, National Institutes of Health, Fredrick, MD, United States.
Justin LackNIAID Collaborative Bioinformatics Resource (NCBR), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Abdalla AbdelmaksoudFrederick National Laboratory for Cancer Research, Advanced Biomedical Computational Science, Fredrick, MD, United States.
Massimo FantiniPrecision Biologics, Inc., Bethesda, MD, United States.
Philip M ArlenPrecision Biologics, Inc., Bethesda, MD, United States.
Kwong Y TsangPrecision Biologics, Inc., Bethesda, MD, United States.
Christina M AnnunziataWomen's Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.
Center for Cancer Research · USNational Institutes of Health · USNational Cancer Institute · USFrederick National Laboratory for Cancer Research · USNational Institute of Allergy and Infectious Diseases · US

Funding

Experimental Pathology Laboratory (EPL)ZICBC011638 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI HEWITT, STEPHEN · 2015 to 2025
$16.6M
Immune cell control of ovarian cancerZIABC011775 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ANNUNZIATA, CHRISTINA · 2017 to 2023
$3.6M
Intramural NIH HHS ZIA BC011775
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

antibody-dependent cellular cytotoxicitycarcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)carcinoembryonic antigen-related cell adhesion molecule (CEACAM6)monoclonal antibodynatural killer celltumor-associated antigen

Identifiers

PMID32637350
PMCPMC7318110
OpenAlexW3036175950

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.